1. Standard therapy potentiation of patients with Stable Angina FC III with concomitant Hypertension through nitric oxide donator L-arginine administration
- Author
-
N. I. Romash, Ivan Romash, M. V. Blyzniuk, Iryna Romash, I. M. Gayova, T. V. Todoriv, N. V. Zozuliak, I. V. Tymkiv, Z. V. Zozuliak, and V. Ye. Neiko
- Subjects
chemistry.chemical_compound ,chemistry ,Arginine ,business.industry ,Concomitant ,Medicine ,Long-term potentiation ,General Medicine ,Pharmacology ,business ,Standard therapy ,Stable angina ,Nitric oxide - Abstract
The purpose of the study was to improve treatment of patients with Stable Angina functional class III (FC) with concomitant arterial hypertension (AH) through a combination of standard therapy with L-arginine. There were examined63 patients with Stable Angina III FK with AH. All patients in the clinic were analyzedby the test with reactive hyperemia, were measured levels of cardio-ankle vascular index, pulse wave velocity, aortic stiffness index and the thickness of the complex "intima-media". It has been established that in studied patients with L-arginine significantly improves endothelium dependent vasodilatation, presumably due to the supply of substrate for the synthesis of nitric oxide, as well as due to antioxidant properties, which prevents the excessive formation of toxic peroxynitrite in conditions of high oxidation stress. Endothelial-independent vasodilation in the standard therapy group was significantly lowered, while in the L-arginine group, the incidence of changes was unreliable, which may indicate a decrease in sensitivity to nitrates in Group I. Thus, the inclusion to antianginal and antihypertensive therapyof L-arginine is more pronouncedaffects subclinical parameters of arterial rigidity, than in the background of treatment with standard therapy.
- Published
- 2018
- Full Text
- View/download PDF